Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition

Livius V. D'Uscio, Thomas Quaschning, John C Jr. Burnett, Thomas F. Lüscher

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

To determine whether natriuretic peptides in addition to the renin-angiotensin system are involved in functional and structural vascular changes in salt-sensitive hypertension, we compared equipotent hypotensive treatment with the dual neutral endopeptidase/ACE inhibitor omapatrilat (35 mg · kg-1 · d-1) or the ACE inhibitor captopril (100 mg · kg-1 · d-1). The reactivity and geometry of mesenteric resistance arteries from Dahl salt-sensitive rats were studied in vitro under perfused and pressurized conditions. Chronic salt administration increased systolic blood pressure by 57±4 mm Hg, whereas concentrations of atrial natriuretic peptide were reduced in heart and in plasma (P<0.05). In addition, the medial cross-sectional area of small mesenteric arteries was increased and endothelium-dependent relaxation in response to acetylcholine and contraction in response to endothelin-1 were impaired in the mesenteric arteries of salt-sensitive rats on a high-salt diet (P<0.05). Concomitant treatment with either omapatrilat or captopril reduced the increase in systolic blood pressure and hypertrophic remodeling to a similar degree (P<0.05) but affected plasma and cardiac atrial natriuretic peptide levels differently (P<0.05). In addition, omapatrilat normalized endothelium-dependent relaxations to a greater extent than captopril (P<0.05). Furthermore, vasopeptidase inhibition increased cGMP levels compared with captopril (P<0.05). Contractions to endothelin-1 were normalized by either antihypertensive drug. These results suggest that in the Dahl rat, with similar reductions in systolic blood pressure, omapatrilat is superior to captopril in preventing impaired endothelial function in small resistance arteries. Thus, vasopeptidase inhibition may have therapeutic advantages of the prevention of changes in vascular function and structure in salt-sensitive forms of hypertension.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalHypertension
Volume37
Issue number1
StatePublished - 2001

Fingerprint

Captopril
Arteries
Salts
Blood Pressure
Hypertension
Mesenteric Arteries
Inbred Dahl Rats
Atrial Natriuretic Factor
Endothelin-1
Angiotensin-Converting Enzyme Inhibitors
Endothelium
Blood Vessels
Neprilysin
Natriuretic Peptides
Renin-Angiotensin System
Protease Inhibitors
Antihypertensive Agents
Acetylcholine
Diet
omapatrilat

Keywords

  • Angiotensin-converting enzyme
  • Arteries
  • Atrial natriuretic peptide
  • Nitric oxide
  • Rats, Dahl
  • Resistance
  • Vasopeptidase

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. / D'Uscio, Livius V.; Quaschning, Thomas; Burnett, John C Jr.; Lüscher, Thomas F.

In: Hypertension, Vol. 37, No. 1, 2001, p. 28-33.

Research output: Contribution to journalArticle

@article{fc1851aba5c441b39846eca1c2e0a3ab,
title = "Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition",
abstract = "To determine whether natriuretic peptides in addition to the renin-angiotensin system are involved in functional and structural vascular changes in salt-sensitive hypertension, we compared equipotent hypotensive treatment with the dual neutral endopeptidase/ACE inhibitor omapatrilat (35 mg · kg-1 · d-1) or the ACE inhibitor captopril (100 mg · kg-1 · d-1). The reactivity and geometry of mesenteric resistance arteries from Dahl salt-sensitive rats were studied in vitro under perfused and pressurized conditions. Chronic salt administration increased systolic blood pressure by 57±4 mm Hg, whereas concentrations of atrial natriuretic peptide were reduced in heart and in plasma (P<0.05). In addition, the medial cross-sectional area of small mesenteric arteries was increased and endothelium-dependent relaxation in response to acetylcholine and contraction in response to endothelin-1 were impaired in the mesenteric arteries of salt-sensitive rats on a high-salt diet (P<0.05). Concomitant treatment with either omapatrilat or captopril reduced the increase in systolic blood pressure and hypertrophic remodeling to a similar degree (P<0.05) but affected plasma and cardiac atrial natriuretic peptide levels differently (P<0.05). In addition, omapatrilat normalized endothelium-dependent relaxations to a greater extent than captopril (P<0.05). Furthermore, vasopeptidase inhibition increased cGMP levels compared with captopril (P<0.05). Contractions to endothelin-1 were normalized by either antihypertensive drug. These results suggest that in the Dahl rat, with similar reductions in systolic blood pressure, omapatrilat is superior to captopril in preventing impaired endothelial function in small resistance arteries. Thus, vasopeptidase inhibition may have therapeutic advantages of the prevention of changes in vascular function and structure in salt-sensitive forms of hypertension.",
keywords = "Angiotensin-converting enzyme, Arteries, Atrial natriuretic peptide, Nitric oxide, Rats, Dahl, Resistance, Vasopeptidase",
author = "D'Uscio, {Livius V.} and Thomas Quaschning and Burnett, {John C Jr.} and L{\"u}scher, {Thomas F.}",
year = "2001",
language = "English (US)",
volume = "37",
pages = "28--33",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition

AU - D'Uscio, Livius V.

AU - Quaschning, Thomas

AU - Burnett, John C Jr.

AU - Lüscher, Thomas F.

PY - 2001

Y1 - 2001

N2 - To determine whether natriuretic peptides in addition to the renin-angiotensin system are involved in functional and structural vascular changes in salt-sensitive hypertension, we compared equipotent hypotensive treatment with the dual neutral endopeptidase/ACE inhibitor omapatrilat (35 mg · kg-1 · d-1) or the ACE inhibitor captopril (100 mg · kg-1 · d-1). The reactivity and geometry of mesenteric resistance arteries from Dahl salt-sensitive rats were studied in vitro under perfused and pressurized conditions. Chronic salt administration increased systolic blood pressure by 57±4 mm Hg, whereas concentrations of atrial natriuretic peptide were reduced in heart and in plasma (P<0.05). In addition, the medial cross-sectional area of small mesenteric arteries was increased and endothelium-dependent relaxation in response to acetylcholine and contraction in response to endothelin-1 were impaired in the mesenteric arteries of salt-sensitive rats on a high-salt diet (P<0.05). Concomitant treatment with either omapatrilat or captopril reduced the increase in systolic blood pressure and hypertrophic remodeling to a similar degree (P<0.05) but affected plasma and cardiac atrial natriuretic peptide levels differently (P<0.05). In addition, omapatrilat normalized endothelium-dependent relaxations to a greater extent than captopril (P<0.05). Furthermore, vasopeptidase inhibition increased cGMP levels compared with captopril (P<0.05). Contractions to endothelin-1 were normalized by either antihypertensive drug. These results suggest that in the Dahl rat, with similar reductions in systolic blood pressure, omapatrilat is superior to captopril in preventing impaired endothelial function in small resistance arteries. Thus, vasopeptidase inhibition may have therapeutic advantages of the prevention of changes in vascular function and structure in salt-sensitive forms of hypertension.

AB - To determine whether natriuretic peptides in addition to the renin-angiotensin system are involved in functional and structural vascular changes in salt-sensitive hypertension, we compared equipotent hypotensive treatment with the dual neutral endopeptidase/ACE inhibitor omapatrilat (35 mg · kg-1 · d-1) or the ACE inhibitor captopril (100 mg · kg-1 · d-1). The reactivity and geometry of mesenteric resistance arteries from Dahl salt-sensitive rats were studied in vitro under perfused and pressurized conditions. Chronic salt administration increased systolic blood pressure by 57±4 mm Hg, whereas concentrations of atrial natriuretic peptide were reduced in heart and in plasma (P<0.05). In addition, the medial cross-sectional area of small mesenteric arteries was increased and endothelium-dependent relaxation in response to acetylcholine and contraction in response to endothelin-1 were impaired in the mesenteric arteries of salt-sensitive rats on a high-salt diet (P<0.05). Concomitant treatment with either omapatrilat or captopril reduced the increase in systolic blood pressure and hypertrophic remodeling to a similar degree (P<0.05) but affected plasma and cardiac atrial natriuretic peptide levels differently (P<0.05). In addition, omapatrilat normalized endothelium-dependent relaxations to a greater extent than captopril (P<0.05). Furthermore, vasopeptidase inhibition increased cGMP levels compared with captopril (P<0.05). Contractions to endothelin-1 were normalized by either antihypertensive drug. These results suggest that in the Dahl rat, with similar reductions in systolic blood pressure, omapatrilat is superior to captopril in preventing impaired endothelial function in small resistance arteries. Thus, vasopeptidase inhibition may have therapeutic advantages of the prevention of changes in vascular function and structure in salt-sensitive forms of hypertension.

KW - Angiotensin-converting enzyme

KW - Arteries

KW - Atrial natriuretic peptide

KW - Nitric oxide

KW - Rats, Dahl

KW - Resistance

KW - Vasopeptidase

UR - http://www.scopus.com/inward/record.url?scp=0035148538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035148538&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035148538

VL - 37

SP - 28

EP - 33

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -